Investment Rating - The report maintains a "Recommended" rating for WuXi AppTec (603259.SH) with a target price of 70.00 CNY [7][8]. Core Views - WuXi AppTec's performance shows a marginal improvement with a robust order backlog contributing to growth momentum. The company achieved a revenue of 39.24 billion CNY in 2024, a decrease of 2.7% year-on-year, but a 5.2% increase when excluding COVID-19 related revenue. Adjusted net profit was 10.58 billion CNY, down 2.5% year-on-year [3][4]. Summary by Sections Financial Performance - In Q4 2024, the company reported a revenue of 11.54 billion CNY, a year-on-year increase of 6.9% and a quarter-on-quarter increase of 10.3%. The net profit attributable to shareholders was 2.92 billion CNY, up 90.6% year-on-year and 27.2% quarter-on-quarter [4]. - The company expects a revenue growth of 10-15% in 2025, projecting revenues between 41.5 billion CNY and 43 billion CNY [4]. Business Outlook - As of the end of 2024, WuXi AppTec added approximately 1,000 new clients, with a backlog of orders reaching 49.31 billion CNY, a year-on-year increase of 47.0%. The capital expenditure for 2024 was 4.0 billion CNY, with expectations to rise to 7.0-8.0 billion CNY in 2025, reflecting strong growth potential [5][8]. Segment Performance - The CRDMO business segment showed resilience, with WuXi Chemistry generating 29.05 billion CNY in revenue, a slight decline of 0.4% year-on-year, while non-COVID revenue grew by 11.2%. The TIDES business segment experienced significant growth, achieving 5.80 billion CNY in revenue, up 70.1% year-on-year [6]. - WuXi Testing reported a revenue of 5.67 billion CNY, down 4.8% year-on-year, while WuXi Biology's revenue was 2.54 billion CNY, a slight decline of 0.3% year-on-year, but showed positive growth trends in Q4 2024 [6]. Financial Projections - The forecast for 2025-2027 indicates a net profit attributable to shareholders of 11.43 billion CNY, 13.19 billion CNY, and 14.95 billion CNY respectively, with corresponding PE ratios of 18, 15, and 14 [8][9]. - Revenue projections for the same period are 43.58 billion CNY, 48.82 billion CNY, and 54.88 billion CNY, with growth rates of 11.0%, 12.0%, and 12.4% respectively [9][10]. Valuation Metrics - The report highlights a projected PE ratio of 21 for 2024, decreasing to 14 by 2027, indicating an improving valuation as earnings grow [9][10]. - The projected PB ratio is expected to decline from 3.4 in 2024 to 2.3 in 2027, reflecting a strengthening financial position [9][10].

Investment Rating - The report maintains a "Buy" rating for both A-shares and H-shares of WuXi AppTec, with current prices at 69.68 CNY and 72.35 HKD respectively [5]. Core Views - WuXi AppTec reported a revenue of 39.241 billion CNY for 2024, a decrease of 2.73% year-on-year, but a 5.2% increase when excluding COVID-19 commercialization projects. The net profit attributable to shareholders was 9.45 billion CNY, down 1.63% year-on-year, while the net profit excluding non-recurring items grew by 2.47% to 9.988 billion CNY, aligning with expectations [1]. - The company experienced a continuous improvement in performance, with a significant increase in backlog orders, reaching 49.31 billion CNY by the end of 2024, a 47% year-on-year growth, indicating robust future revenue support [1]. - The TIDES business segment showed remarkable growth, with a 70.1% year-on-year increase in revenue to 5.8 billion CNY, and a 103.9% growth in related backlog orders [2]. Summary by Sections Financial Performance - For Q4 2024, WuXi AppTec achieved a revenue of 11.54 billion CNY, a quarter-on-quarter increase of 10.31%, and a net profit of 2.92 billion CNY, up 27.22% quarter-on-quarter [1]. - The gross margin improved by 0.68 percentage points to 43.46% [1]. Business Segments - The chemical business generated a revenue of 29.05 billion CNY in 2024, with an 11.2% year-on-year growth when excluding specific projects. The small molecule D&M business contributed 17.87 billion CNY, with a 6.4% growth excluding COVID-19 projects [2]. - The TIDES business is expected to expand capacity significantly, with the total volume of peptide solid-phase synthesis reactors increasing to 41,000 liters by the end of 2024 and projected to exceed 100,000 liters by the end of 2025 [2]. Profit Forecast and Valuation - The profit forecasts for 2025-2027 have been revised upwards, with net profit estimates of 10.978 billion CNY for 2025, 12.516 billion CNY for 2026, and 14.147 billion CNY for 2027, reflecting year-on-year growth rates of 16.2%, 14.0%, and 13.0% respectively [3]. - The corresponding price-to-earnings ratios for A-shares are projected to be 18, 16, and 14 for 2025, 2026, and 2027 respectively, while for H-shares, they are expected to be 18, 15, and 14 [3].

Investment Rating - The report maintains a "Buy" rating for both A-shares and H-shares of WuXi AppTec, with current prices at 69.68 CNY and 72.35 HKD respectively [5]. Core Insights - WuXi AppTec reported a revenue of 39.241 billion CNY for 2024, a decrease of 2.73% year-on-year, but a 5.2% increase when excluding COVID-19 commercialization projects. The net profit attributable to shareholders was 9.45 billion CNY, down 1.63% year-on-year, while the net profit excluding non-recurring items grew by 2.47% to 9.988 billion CNY, aligning with expectations [1]. - The company experienced a significant increase in backlog orders, reaching 49.31 billion CNY by the end of 2024, a 47% year-on-year growth, indicating robust future revenue support [1]. - The TIDES business segment saw a remarkable growth of 70.1% year-on-year, generating 5.8 billion CNY in revenue, with backlog orders increasing by 103.9% [2]. Summary by Sections Financial Performance - In Q4 2024, WuXi AppTec achieved a revenue of 11.54 billion CNY, a quarter-on-quarter increase of 10.31%, and a net profit of 2.92 billion CNY, up 27.22% quarter-on-quarter [1]. - The gross margin improved by 0.68 percentage points to 43.46% due to favorable currency exchange rates and investment income from the reduction of Wuxi XDC [1]. Business Segments - The chemical business generated 29.05 billion CNY in revenue for 2024, with an 11.2% year-on-year growth when excluding specific projects. The small molecule D&M business contributed 17.87 billion CNY, growing 6.4% year-on-year [2]. - The TIDES business is expected to continue its rapid expansion, with production capacity projected to exceed 100,000 liters by the end of 2025 [2]. Profitability and Valuation - The net profit forecasts for 2025-2027 have been revised upwards to 10.978 billion CNY, 12.516 billion CNY, and 14.147 billion CNY respectively, reflecting year-on-year growth rates of 16.2%, 14.0%, and 13.0% [3]. - The report indicates that the A-share price-to-earnings (P/E) ratios for 2025-2027 are projected to be 18, 16, and 14 times, while the H-share P/E ratios are expected to be 18, 15, and 14 times [3].

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 药明康德(603259) [Table_Author] 唐爱金 医药首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 贺鑫 医药行业分析师 执业编号：S1500524120003 邮 箱：hexin1@cindasc.com 相关研究 [Table_OtherReport] 维持全年指引不变，TIDES 业务逆势增 长 药明康德(603259)：高基数下稳定增 长，盈利能力持续提升 药明康德(603259)：业绩符合预期， 多业务协同稳健发展 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B [Table_Title] 业绩边际改善趋势明确，2025 年有望实现双 位数增长 [Table_ReportDate] 2025 年 03 月 18 日 [Table_S 事件：2025 ummar年y]3 月 17 日，公司发布《2024 年年度报告》。2024 年公司实 现营业收 ...

Investment Rating - The report maintains a positive outlook for WuXi AppTec, indicating a potential for double-digit growth in 2025 [2][3]. Core Insights - The company achieved a revenue of 39.24 billion yuan in 2024, a decrease of 2.7% year-on-year, but a 5.2% increase when excluding COVID-19 commercialization projects. The net profit attributable to shareholders was 9.45 billion yuan, down 1.6% year-on-year, while the adjusted net profit increased by 2.5% to 9.99 billion yuan [1][2]. - The revenue for Q4 2024 was 11.54 billion yuan, reflecting a quarter-on-quarter growth of 10.3% and a year-on-year growth of 6.9%. The adjusted net profit for Q4 was 3.24 billion yuan, up 20.4% year-on-year [2][3]. - The company expects revenue from continuing operations to return to double-digit growth in 2025, with a projected revenue of 41.5 to 43 billion yuan, representing a growth of 10% to 15% [2][3]. Summary by Sections Financial Performance - In 2024, the company reported quarterly revenues of 7.98 billion yuan, 9.26 billion yuan, 10.46 billion yuan, and 11.54 billion yuan, with adjusted net profits of 1.91 billion yuan, 2.46 billion yuan, 2.97 billion yuan, and 3.24 billion yuan respectively [2]. - The total revenue for 2024 was 39.24 billion yuan, with a year-on-year growth rate of -2.7%. The adjusted net profit was 10.58 billion yuan, down 2.5% year-on-year [1][2]. Business Segments - The chemical business generated 29.05 billion yuan in 2024, a slight decline of 0.4%, but a growth of 11.2% when excluding specific commercialization projects. The TIDES business saw a significant revenue increase of 70.1% to 5.8 billion yuan [3][4]. - The testing business reported a revenue of 5.67 billion yuan, down 4.8% year-on-year, primarily due to a decline in order prices [4][5]. - The biological business achieved a revenue of 2.54 billion yuan, with a 29.9% growth in non-tumor-related areas [5][6]. Future Outlook - The company plans to increase capital expenditures to 7 to 8 billion yuan in 2025, focusing on expanding global D&M capacity [7]. - Revenue projections for 2025 to 2027 are 42.32 billion yuan, 47.08 billion yuan, and 52.24 billion yuan respectively, with net profits expected to reach 11.02 billion yuan, 12.50 billion yuan, and 14.09 billion yuan [8][9].

2025 年 3 月 12 日 招银国际环球市场 | 睿智投资 | 行业研究 中国医药 海外 CXO/生命科学上游 2024 和 4Q24 业绩剖析：C(D)MO 和生命科学上游表现亮眼，临床 CRO 需求滑坡 我们总结了海外主要 CXO 和生命科学上游公司的 2024 和 4Q24 业绩情况，所关注的 公司涉及临床 CRO、临床前 CRO、C(D)MO 以及生命科学上游。我们跟踪公司的 24 年收入和利润增长仍然承压，但有一半的公司 2H24 业绩表现相比 1H24 出现改善。 C(D)MO 和生命科学上游公司在业绩改善、需求展望和业绩指引方面均展现出积极趋 势；而临床 CRO 公司在 24 年下半年遇到了需求滑坡，相关公司对 25 年业绩指引普 遍保守。此外，我们认为 24 年 biotech 需求并没有实质改善，这将继续压制 25 年临 床前 CRO 的业绩表现。 估值表 | | | | 市值 | 目标价 | 上行/ | | 收入 CAGR 净利润 CAGR | P/E (x) | | PEG | | --- | --- | --- | --- | --- | --- | --- | --- | --- ...

证券研究报告 | 行业周报 gszqdatemark 2025 03 01 年 月 日 医药生物 【周专题&周观点】【总第 386 期】2024 快报高增长公司梳理— —前三季度高增长公司列举 一、当周（2.24-2.28）回顾与周专题： 当周（2.24-2.28）申万医药指数环比-2.72%，跑赢创业板指数，跑输沪深 300 指数。 当周周专题，我们梳理了 2024 快报高增长的医药公司，并列举了前三季度高增长公司， 供投资者寻找 2024 年业绩超预期的潜在标的。 （二）【AI 医疗应用】国际医学、九安医疗、晶泰控股、美年健康、华大智造、华大基 因、金域医学、固生堂、医脉通等。 （三）【两会政策】生育如华特达因；体检如美年健康。 （四）【其他标的】健友股份、福瑞股份、药明康德、浩欧博、哈药股份等。 2、思路二【医药产业逻辑】 2、原因分析：主要系相关标的涨幅较大且海外映射偏弱，从科技主线演绎到两会。我 们认为：（1）AI 医疗此次调整和去年短期行情不太一样，市场慢慢认识到了 AI 之于医 药医疗未来行业演变的意义，但经过一轮演绎后，医疗 AI 会快速去伪存真，第二波应 该会更聚焦，围绕【场景/入口、数据】 ...

Market Review - The overall market sentiment for the pharmaceutical sector remains cautious, with the CITIC Pharmaceutical Index declining by 2.78%, underperforming the CSI 300 Index by 0.56 percentage points, ranking 21st among 30 primary industries [4] - The top ten stocks by growth this week include Nuo Cheng Jian Hua-U, Chang Yao Holding, and Shanghai Yi Zhong, with growth rates of 20.98%, 20.96%, and 18.78% respectively [3][4] - Conversely, the bottom ten stocks include Jiangsu Wu Zhong and Xin Gan Jiang, with declines of 4% and 6% respectively [4] Industry and Stock Events - The pharmaceutical sector's valuation is currently low, with public funds (excluding pharmaceutical funds) also underweight in this sector. The outlook for the pharmaceutical industry in 2025 remains optimistic due to macroeconomic factors such as the recovery of US Treasury yields and the driving effect of large categories and products [7] - In the innovative drug segment, there is a shift from quantity logic to quality logic, emphasizing the importance of product differentiation and internationalization. Companies to watch include Heng Rui, Bai Ji, and Nuo Cheng Jian Hua [7] - The medical device sector is expected to benefit from the acceleration of equipment renewal policies, with key companies like Mai Rui Medical and Xin Hua Medical positioned to gain from increased orders [7] - The IVD market is anticipated to return to high growth, with a focus on companies like An Tu Biology and Di Rui Medical, as domestic market penetration continues to expand [7] - The blood products sector is set for growth, with a favorable regulatory environment for plasma collection and increasing demand post-pandemic. Companies such as Tian Tan Biology and Bo Ya Biology are recommended [12] Antibiotics Industry Update - The global antibiotic market is projected to grow steadily, with a market size of approximately 98 billion yuan in China from 2017 to the third quarter of 2024. The top three hospital antibiotics in 2024 are expected to be injectable formulations of Piperacillin and Tazobactam, with sales of 4.94 billion yuan [15][16] - The production capacity for key antibiotic intermediates is under strict regulatory control, with the latest guidelines from the National Development and Reform Commission continuing to restrict new capacity in antibiotic intermediates [17] - The price trends for key antibiotic products such as Penicillin and 6-APA have shown fluctuations, with 6-APA's price reaching 320 yuan per kilogram by January 2025 [24][25]

Investment Rating - The investment rating for the industry is maintained at "Buy" [3] Core Insights - The report highlights a recovery process for the CXO sector, driven by a rebound in global healthcare investment and the potential of AI in drug development [6][9][10] - The FDA has granted priority review status to a potential "first-in-class" small molecule for cancer treatment, indicating significant advancements in the pharmaceutical pipeline [3][43] Market Performance Review - The Shanghai Composite Index closed at 3379.11, up 0.97%, while the Shenzhen 300 Index rose by 1.00% [1] - The pharmaceutical industry index increased by 0.96%, ranking 8th among 31 primary industry indices [1] - Weekly performance of various segments within the pharmaceutical industry showed mixed results, with traditional Chinese medicine down by 2.30% and medical services up by 6.87% [1] CXO Recovery Process - Global healthcare investment is showing signs of recovery, with 2024 global pharmaceutical investment amounting to $57.747 billion, a slight decline of 1% year-on-year, significantly narrowing from a 34% drop in 2023 [7][22] - Domestic investment in the pharmaceutical sector for 2024 is projected at 517.97 billion yuan, also reflecting a narrowing decline [7][22] - The failure of the 2024 Biodefense Act to pass is expected to alleviate valuation pressures on CXO companies [8][28] AI Empowerment in Drug Development - The rise of artificial intelligence is transforming drug development, addressing challenges such as long development cycles and high costs [9][29] - Companies that achieve breakthroughs in AI applications within the CXO sector are likely to gain competitive advantages in future drug development [9][29] Industry News - The RuiPath pathology model, developed by Huawei and Ruijin Hospital, aims to enhance diagnostic accuracy and efficiency in pathology [2][43] - Chimerix's dordaviprone has received FDA priority review, marking a significant milestone for potential cancer therapies [3][43]

适时转身。 投资界（PEdaily.cn）旗下，专注并购动态 以下文章来源于并购最前线 ，作者岳笑笑 并购最前线 . 作者 I 岳笑笑 先来看并购的两位主角—— 根据公开资料，收购方奥浦迈是一家专门从事细胞培养产品与服务的科技型企业，曾在 20 22年登陆科创板，被称作"细胞培养基CDMO第一股"。巅峰时期，公司市值一度超过 10 0亿元，但随后股价持续下滑，如今市值浮动在45亿元左右。 宣布收购前，奥浦迈业绩持续下滑。2 02 2年及2023年，公司的营业收入分别为2.94亿 元、2. 4 3亿元；毛利率分别为 6 3. 9 7%、58.85%；归母净利润分别为1.05亿元、0. 5 4亿 元。前不久发布的业绩预告更是显示，公司2024年预计实现归母净利润0.20亿元，同比 下降62 . 37%。 奥浦迈迫切需要一条出路。于是在去年11月，公司公告拟出资不超过3亿元参设产业投资 基金，对中国境内生物制造、制药设备和耗材、生物医药等领域的早中期项目和并购项 目进行投资活动。此前奥浦迈还称，投资并购是公司一直想做的事情，具体的进展会根 据公司实际情况推进。 报道 I 投资界-并购最前线 医药圈又诞生一例并购案。 ...